臺灣博碩士論文加值系統

背景：直腸癌的治療，以手術切除為主要治療方式。然而，局部復發
是最大的挑戰。透過全直腸係膜切除（total mesorectal excision）和同步化學及放射線治療（concurrent chemoradiotherapy）能有效地降低局部復發率（local recurrent rate）。術前同步化學及放射線治療在肛門保留（sphincter preservation）及完全切除率（complete resection rate）
都優於術後同步化學治及放射線治療。口服UFUR比連續靜脈注射5-FU還方便。本研究比較口服UFUR與靜脈注射5-FU於直腸癌患者接受術前同步化學及放射線治療的治療差異。
方法：本研究從西元2001一月至西元2010年12月，共有57位患者進入此研究。口服UFUR這組患者，接受放射線治療（4500 cGy平均分成五週）及化學治療（300mg/m2/day UFT and 25mg/day oral LV），於治療前六週給予。靜脈注射5-FU這組患者，接受放射線治療（4500 cGy平均分成五週）及化學治療（每週接受5-FU 3000mg/m2 連續給予 24 hours），於治療前六週給予。使用統計軟體（SPSS 14.0，SPSS Inc.，Chicago，IL，U.S.A）進行統計層次分析。數值變項使用ｔ檢定分析；類別變項使用χ2檢定分析。
結果：口服UFUR這組有28位病患，而靜脈注射5-FU這組患者有29位病患。這兩組在腫瘤反應率（response rate）上沒有統計學差異（50.0% vs 38.0%, p=0.171）。腫瘤完全反應率（complete
response rate）在口服UFUR這組為14.3%，而靜脈注射5-FU這組為13.8%。於接受術前同步化學及放射線治療期間，並沒有患者疾病惡化或是轉移。
結論：直腸癌患者接受術前同步化學及放射線治療時，不管是使用
口服UFUR 或是靜脈注射5-FU，都有相同的腫瘤反應率和腫瘤完全
反應率。

Background：Surgical resection has been the main force of rectal cancer treatment. However, local recurrence has been the most challenge.
Total mesorectal excision and concurrent chemo-radiotherapy can effectively reduce the local recurrence rate. Pre-operative concurrent chemo-radiotherapy is superior to post-operative concurrent chemo-radiotherapy in anal sphincter preservation and complete resection. UFUR is more convenient than infusion 5-FU.
We compared oral uracil and tegafur plus leucovorin vs. infusion 5-fluorouracil plus leucovorin given concomitantly with preoperative irradiation in patients with low rectal cancer.
Materials and Methods：A total of 57 patients were included into this study between Jan 2001 to Dec 2010. Oral UFT group received pelvic radiation（4500 cGy in 5 weeks）and chemotherapy（300mg/m2/day UFT and 25mg/day oral LV）in the first 6 weeks. Infusion group patient received pelvic radiation（4500 cGy in 5 weeks）and chemotherapy （5-FU weekly 3000mg/m2 keep 24 hours）in the first 6 weeks.
Statistical analysis was carried out by using the statistical software (SPSS 14.0; SPSS Inc., Chicago, IL, USA). The chi-square test was used to compare categorical data and the Student’s t test was use to compare numerical data.
Results：There were 28 patients in oral UFT group and 29 patients in infusion group. There were no differences in response rates （50.0% vs 38.0%, p=0.171） The pCT rate was 14.3% in oral UFT group and 13.8% in infusion group. During pre-OP CCRT period, no patients were suffered from disease progress or metastasis.
Conclusion：Oral UFUR and intravenous infusional 5- fluorouracil in preoperative concurrent chemoradiotherapy for rectal cancer are effective in tumor response rate and pathologic complete response.

中文摘要 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ V
英文摘要 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ VII
誌謝 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ IX
目錄 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ I
表目錄 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ III
圖目錄 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ IV
第一章 前言 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 1
第二章 文獻探討 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 3
第一節 直腸的解剖構造簡介 ‥‥‥‥‥‥‥‥‥‥‥‥ 3
第二節 直腸癌的流行病學 ‥‥‥‥‥‥‥‥‥‥‥‥‥ 4
第三節 直腸癌的症狀‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 6
第四節 直腸癌的診斷方法 ‥‥‥‥‥‥‥‥‥‥‥‥‥ 9
第五節 直腸癌的治療 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 11
第六節 直腸癌術前同步化學及放射線治療的角色 ‥‥‥ 13
第三章 直腸癌術前同步化學及放射線治療的臨床意義 ‥‥ 15
第一節 直腸癌術前放射線治療簡介 ‥‥‥‥‥‥‥‥ 15
第二節 直腸癌術前化學治療簡介 ‥‥‥‥‥‥‥‥‥ 16
第三節 Tegafur/Uracil (UFUR®) 藥理作用簡介 ‥‥‥ 17
第四章 研究對象與方法 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 20
第一節 研究對象 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 20
第二節 研究方法 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 20
第五章 結果 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 22
第一節 兩組患者基本資料之比較 ‥‥‥‥‥‥‥‥‥ 22
第二節 兩組患者術前同步化學及放射線治療療效之
比較 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 23
第六章 討論 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 24
第七章 結論與未來展望 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 26
參考文獻 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 38

1. The ASCRS Textbook of Colon and Rectal Surgery, P4-P7

2. Sabiston Textbook of Surgery, 18th ed., Chapter 50

3. Casado et al. ; Annals of Oncology 19: 1371–1378, 2008

4. Bureau of Health Promotion, Department of Health, R.O.C.
(Taiwan)
http://www.bhp.doh.gov.tw/bhpnet/portal/Them_Show.aspx
?Subject=200802140005&Class=2&No=200907210002

5. Johns LE, Houlston RS. A systematic review and
meta-analysis of familial colorectal cancer risk
Am J Gastroenterol 2001;96(10):2992–3003.

6. Lynch HT, de la Chapelle A. Hereditary colorectal cancer.
N Engl J Med 2003;348(10):919–932.

7. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard
O. Randomised study of screening for colorectal cancer with
faecaloccult-blood test. Lancet 1996;348:1467–1471.

8. Hardcastle JD, Chamberlain JO, Robinson MH, et al.
Randomised controlled trial of faecal-occult-blood
screening for colorectal cancer. Lancet
1996;348:1472–1477.

9. Mandel JS, Bond JH, Church TR, et al. Reducing mortality
from colorectal cancer by screening for fecal occult blood.
Minnesota Colon Cancer Control Study. N Engl J Med
1993;328:1365–1371.

10. Newcomb P, Norfleet R, Storer B, Surawicz T, Marcus P.
Screening sigmoidoscopy and colorectal cancer mortality.
J Natl Cancer Inst 1992;84:1572–1575.

11. Muller AD, Sonnenberg A. Protection by endoscopy against
death from colorectal cancer. A case-control study among
veterans. Arch Intern Med 1995;155:1741–1748.

12. Selby J, Friedman G, Quesenberry C, Weiss N. A case-control
study of screening sigmoidoscopy and mortality from
colorectal cancer. N Engl J Med 1992;326:653–657.

13. Steine S, Stordahl A, Lunde OC, Loken K, Laerum E.
Doublecontrast barium enema versus colonoscopy in the
diagnosis of neoplastic disorders: aspects of
decision-making in general practice. Fam Pract
1993;10:288–291.

14. Hixson LJ, Fennerty MB, Sampliner RE, McGee D, Garewal H.
Prospective study of the frequency and size distribution
of polyps missed by colonoscopy. J Natl Cancer Inst
1990;82:1769–1772.

15. Hixson LJ, Fennerty MB, Sampliner RE, Garewal HS.
Prospective blinded trial of the colonoscopic miss-rate of
large colorectal polyps. Gastrointest Endosc
1991;37:125–127.

16. Fork FT. Double contrast enema and colonoscopy in polyp
detection. Gut 1981;22:971–977.

17. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard
O. Randomised study of screening for colorectal cancer with
faecaloccult- blood test. Lancet 1996;348:1467–1471.

18. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG.
Screening for colorectal cancer with fecal occult blood
testing and sigmoidoscopy. J Natl Cancer Inst
1993;85:1311–1318.

19. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of
colorectal cancer by colonoscopic polypectomy.
The National Polyp Study Workgroup. N Engl J Med
1993;329:1977–1981.

20. Muller AD, Sonnenberg A. Protection by endoscopy against
death from colorectal cancer. A case-control study among
veterans. Arch Intern Med 1995;155:1741–1748.

21. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer
screening: clinical guidelines and rationale.
Gastroenterology 1997;112:594–642.

22. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer
incidence and mortality in Europe in 2006. Ann Oncol 2007;
18: 581–592.

23. Tveit K. ESMO Guidelines Task Force. ESMO minimum clinical
recommendations for diagnosis, treatment and follow-up of
rectal cancer. Ann Oncol 2005; 16 (Suppl 1): i20–i21.

24. Sauer R, Becker H, Hohenberger W et al. Preoperative versus
postoperative chemoradiotherapy for rectal cancer. N Engl
J Med 2004; 351: 1731–1740.

25. Bosset JF, Collette L, Calais G et al. Chemotherapy with
preoperative radiotherapy in rectal cancer. N Engl J Med
2006; 355: 1114–1123.

26. National Comprehensive Cancer Network. Clinical Practice
Guidelines in Oncology. Rectal Cancer. V1.2008.
http://www.nccn.org/professionals/physician_gls
/PDF/rectal.pdf(12 February 2008, date last accessed)

27. Glimelius B, Gronberg H, Jarhult J, Wallgren A,
Cavallin-Stahl E. A systematic overview of radiation
therapy effects in rectal cancer. Acta Oncol
2003;/42:/476 92.


28. Ahmad NR, Marks G, Mohiuddin M. High-dose preoperative
radiation for cancer of the rectum: Impact of radiation
dose on patterns of failure and survival. Int J Radiat Oncol
Biol Phys 1993;27:773–778.

29. Swedish Rectal Cancer Trial: initial report from a Swedish
multicentre study examining the role of preoperative
irradiation in the treatment of patients with resectable
rectal carcinoma. Br J Surg 1993;80:1333–1336.

30. Videtic GM, Fisher BJ, Perera FE, et al.: Preoperative
radiation with concurrent 5-fluorouracil continuous
infusion for locally advanced unresectable rectal cancer.
Int J Radiat Oncol Biol Phys 1998;42:319–324.

31. Minsky BD, Cohen AM, Enker WE, et al.: Preoperative 5-FU,
low-dose leucovorin, and radiation therapy for locally
advanced and unresectable rectal cancer. Int J Radiat Oncol
Biol Phys 1997;37:289–295.

32. Chen ET, Mohiuddin M, Brosovsky H, et al.: Downstaging of
advanced rectal cancer following combined preoperative
chemotherapy and high dose radiation. Int J Radiat Oncol
Biol Phys 1994;30:169–175.

33. Chan A, Wong A, Langevin J, et al.: Preoperative concurrent
5-fluorouracil infusion, mitomycin-c and pelvic radiation
therapy in tethered and fixed rectal carcinoma.
Int J Radiat Oncol Biol Phys 1993;25:791–799.

34. Janjan NA, Khoo VS, Abbruzzese J, et al.: Tumor down staging
and sphincter preservation with preoperative
chemoradiation in locally advanced rectal cancer: The M.D.
Anderson Cancer Center Experience. Int J Radiat Oncol Biol
Phys 1999;44:1027–1038.

35. Valentini V, Coco C, Cellini N, et al.: Preoperative
chemoradiation with cisplatin and 5-fluorouracil for
extraperitoneal T3 rectal cancer: Acute toxicity, tumor
response, and sphincter preservation. Int J Radiat Oncol
Biol Phys 1999;45:1175–1184.

36. Rich TA, Skibber JM, Ajani JA, et al.: Preoperative
infusional chemoradiation therapy for stage T3 rectal
cancer. Int J Radiat Oncol Biol Phys 1995;32:1025–1029.

37. http://140.116.253.135/NewHomePage/manager/form/drug
/description/384726UFUR.pdf

38. F. A. CALVO et al. ; Int. J. Radiation Oncology Biol. Phys.,
Vol. 51, No. 5, pp. 1264–1270, 2001